Merck, Hansoh and Obesity

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.
Merck in Pact for Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
Merck signs up to $2 billion obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug. Under the deal, Merck will pay $112 million upfront and Hansoh will be eligible to receive up to $1.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.
Merck enters obesity drug race in pact with Chinese pharma Hansoh
Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at weight loss and other cardio metabolic conditions.

U.S. Obesity Rate Drops for 1st Time in a Decade

Obesity giants will begin $80 bln M&A face-off
Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...
A New Way To Treat Obesity? Scientists Expose a Secret Appetite-Regulating Circuit in the Brain
A previously unknown population of neurons in the hypothalamus may pave the way for new obesity treatments. Obesity impacts a ...
Here's the new rule that would expand coverage for anti-obesity medications in Medicare and Medicaid
The Biden administration has unveiled a major proposal to expand Medicare and Medicaid coverage for anti-obesity drugs, ...
Science-Based Medicine1h
RFK Jr On Obesity
We have been giving a lot of attention to RFK Jr recently, with good reason. He is poised to be put in charge of the federal ...
The American Journal of Managed Care16h
Top 5 Most-Read Obesity Articles in 2024
The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.
Pennsylvania Medicaid spent nearly $300 million on Wegovy and other anti-obesity drugs
Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...
Hosted on MSN19h
Endocrinologist Deserts; U.S. Obesity Declines; New Obesity Definition Coming Soon
Almost 70% of U.S. counties are "endocrinologist deserts," meaning they lack a single practicing endocrinologist, according ...